Advanced refractory #AdrenalCarcinoma treated with #lenvatinib (20mg) and #pembrolizumab ORR 27% mPFS 10.4m Grade 3 tox - 76.7% @myESMO #ESMO26 #ESMOAmbassadors

@myESMO Agreed #ThomasWalter We need prospective studies @myESMO #ESMO26 #ESMOAmbassadors

First-line chemo + #Obrixtamig from #DAREON7 by @Ja_Capdevila Results by DLL3 status: high vs low More CRS if DLL3 high? ORR higher in DLL3 high, but still 65% in DLL3 low (good) DAREON-NEC-1 - recruiting in Spain (including @Hospital_FJD) @myESMO #ESMO26 #ESMOAmbassadors

[212Pb]VMT-a-NET PRRT phase I/IIa trial by @OncoThor 67 patients ORR 33-40% - durable PFS not mature No Dysphagia/MDS @myESMO #ESMO26 #ESMOAmbassadors

#SSA beyond #progression in G1/2 NETs Improved PFS with PRRT and targeted therapies Caution: Retrospective study @myESMO #ESMO26 #ESMOAmbassadors

#Surufatinib + PlatEtop + serplulimab in epNECs @myESMO #ESMO26 #ESMOAmbassadors